23-10-05	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
21-06-18	CBDMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	2023-02-28
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	2018-12-31
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	2017-02-28
William Raines BRD	Director/Board Member	66	2019-04-18
Scott Stephen CHM	Chairman	60	2022-06-02

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.6859 $	-1.73%	93,799
26-06-11	0.6980 $	+0.87%	79,925
26-06-10	0.6920 $	-3.22%	104,217
26-06-09	0.7150 $	-0.69%	195,735
26-06-08	0.7200 $	-0.48%	147,058

Delayed Quote NYSE

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6859USD

Average target price

2.000USD

Spread / Average Target

+191.59%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	7.2M 6.22M 5.73M 5.36M 10.05M 684M 10.21M 67.65M 26.38M 333M 27.02M 26.44M 1.15B	P/E Ratio 2026 *	-3.61x	P/E Ratio 2027 *	-9.8x
Enterprise Value	7.2M 6.22M 5.73M 5.36M 10.05M 684M 10.21M 67.65M 26.38M 333M 27.02M 26.44M 1.15B	EV / Sales 2026 *	0.32x	EV / Sales 2027 *	0.31x
Free-Float	89.32%	Yield 2026 *	-	Yield 2027 *	-

05-14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
04-01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI
02-17	CbdMD, Inc., Q1 2026 Earnings Call, Feb 17, 2026
02-17	CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-02	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI
01-29	CbdMD, Inc. Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	CI
01-14	cbdMD announces strategic acquisition of Bluebird Botanicals	RE
01-13	CbdMD, Inc. acquired assets of Gaia Botanicals, LLC for $1 million.	CI
12-19	CbdMD, Inc., Q4 2025 Earnings Call, Dec 19, 2025
12-19	CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI

05-14	CbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum	PR
05-12	CbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results	PR
04-01	CbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	PR
02-17	CbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026	PR
02-12	CbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results	PR

1 day	-1.73%
1 week	-5.20%
Current month	-13.40%
1 month	-13.81%
3 months	-3.39%
6 months	-42.84%
Current year	-49.19%

1 week	0.67	0.74
1 month	0.67	0.86
Current year	0.63	1.34
1 year	0.47	2.56
3 years	0.47	17.52
5 years	0.47	1,170.36
10 years	0.47	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
04-13	Sibyl Swift	Free	Chief Technology Officer	1,572	0.0150%
04-13	Jeffrey Porter	Free	Director	1,572	0.0150%
04-13	William Raines	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	-1.73%	-5.20%	-20.15%	-94.93%	7.2M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+38.28%	+154.20%	1,010B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.32%	+49.85%	580B
ABBVIE INC.	+1.32%	+0.22%	+19.18%	+64.65%	402B
ROCHE HOLDING AG	+0.77%	0.00%	+21.28%	+16.70%	330B
NOVARTIS AG	+0.44%	+3.48%	+25.65%	+35.66%	281B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.54%	+14.67%	280B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.35%	-47.35%	197B
AMGEN INC.	+0.32%	+1.61%	+20.32%	+60.01%	192B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+14.19%	+60.09%	156B
Average	+0.04%	+0.24%	+15.03%	+31.35%	342.89B
Weighted average by Cap.	-0.23%	+1.04%	+27.77%	+70.54%

	2026 *	2027 *
Net sales	22.15M 19.13M 17.63M 16.5M 30.93M 2.11B 31.41M 208M 81.17M 1.02B 83.14M 81.37M 3.55B	23.26M 20.09M 18.51M 17.33M 32.48M 2.21B 32.98M 219M 85.23M 1.08B 87.3M 85.44M 3.73B
Net income	-1.9M -1.64M -1.51M -1.42M -2.66M -181M -2.7M -17.87M -6.97M -88M -7.14M -6.99M -305M	-902K -779K -718K -672K -1.26M -85.74M -1.28M -8.48M -3.31M -41.73M -3.39M -3.31M -144M
Net Debt	-	-